Greenwich Lifesciences Inc Stock Price, News & Analysis

Greenwich LifeSciences, Inc. (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, reports its significant achievements, including a 763% increase in share price since its IPO in February 2019, the highest among 307 biotech IPOs. The company is pleased with H.C. Wainwright's analyst coverage initiation on September 1, 2021, with a price target of $78 per share. It has also been added to the Russell 2000 index, enhancing its visibility to institutional investors. Upcoming updates on GP2 immunotherapy and Phase III clinical trial initiation are anticipated.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced its participation in Citi's 16th Annual BioPharma Virtual Conference, taking place from September 8-10, 2021. CEO Snehal Patel will engage in one-on-one meetings with investors. The conference features key discussions and presentations from leading pharma and biotech companies. Greenwich focuses on developing GP2, an immunotherapy aimed at preventing breast cancer recurrences. Previous Phase IIb trials showed no recurrences in high HER2 positive patients after treatment, and a Phase III trial is planned.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced its inclusion in the Russell 2000® and Russell 3000® Indexes effective June 28, 2021. This milestone is expected to boost institutional ownership and visibility for the company as it develops GP2, an immunotherapy aimed at preventing breast cancer recurrences. CEO Snehal Patel emphasized the significance of this addition and the plans for a Phase III clinical trial. The Russell Indexes are benchmarks for $10.6 trillion in assets, highlighting the potential for increased interest in GLSI.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) presented the final 5-year safety data of its GP2 immunotherapy at the 2021 ASCO Annual Meeting. The Phase IIb trial showed no serious adverse events related to GP2, with the majority experiencing mild injection site reactions. Notably, completion of the GP2 Primary Immunization Series led to a 0% recurrence rate in HER2 3+ patients over five years post-surgery. The findings support plans for a Phase III trial, leveraging the encouraging safety data to attract potential partners for co-development.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has appointed Christine Fischette, Ph.D., as Vice President of Business Development. Dr. Fischette aims to expand the company’s pipeline and pursue strategic partnerships for its immunotherapy product, GP2, which has shown promising results in preventing breast cancer recurrences. The final safety data from a Phase IIb trial will be presented at the upcoming ASCO conference, which, if positive, could enhance GP2's market appeal. CEO Snehal Patel emphasized that Dr. Fischette's experience will be vital as they target new breast cancer markets.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has announced the publication of a second poster detailing the GP2 Phase III clinical trial design at the 2021 AACR Annual Meeting. Led by Dr. Mothaffar F. Rimawi, the trial aims to treat up to 500 patients to evaluate GP2 as an immunotherapy to prevent breast cancer recurrences post-surgery. The trial is based on promising Phase IIb results showing 100% invasive Disease-Free Survival (iDFS) after 5 years. An interim analysis is planned, and the trial will explore expanding the treatment for various HLA types.

Greenwich LifeSciences (Nasdaq: GLSI) presented final immune response data from a 5-year Phase IIb clinical trial of GP2, an immunotherapy for preventing breast cancer recurrences, at the 2021 AACR Annual Meeting. The study showed that those completing the GP2 treatment had a 0% recurrence rate over five years. Significant peak immunity was achieved after 6 months of GP2 treatment, with positive immune responses observed in both HER2 3+ and HER2 1-2+ populations. These results suggest potential broader applications for GP2 in treating other HER2-related cancers.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced the final 5-year immune response data from its Phase IIb clinical trial at the 2021 AACR Annual Meeting. This data is crucial for developing dosing strategies for GP2, an immunotherapy aimed at preventing breast cancer recurrences. The AACR published the data abstract on April 9, with a poster to be released on April 10. Additional updates on Phase III trial design are expected the week of April 12, and safety data presentations are scheduled for the ASCO conference on June 4.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced CEO Snehal Patel's participation in the Benzinga Biotech Small-Cap Conference on March 24, 2021. He will be involved in a 30-minute immunotherapy oncology panel at 10:25 am EST and a live 15-minute presentation at 12:35 pm EST, followed by a Q&A session. The company is focused on developing GP2, an immunotherapy intended to prevent breast cancer recurrences in previously treated patients. The Phase IIb trial showed promising results with no recurrences after five years.